Ruedi Aebersold will return to Switzerland next year to join the Swiss Federal Institute of Technology Zurich (ETH Zurich) as professor of systems biology. Aebersold will continue to serve full-time at the Institute for Systems Biology in Seattle until the end of 2004 or early 2005, at which point he will begin to spend most of his time at ETH Zurich while retaining a faculty position at ISB.
After moving to Switzerland, Aebersold will spend 20 to 25 percent of his time at ISB, where he will focus on developing bioinformatics for proteomics, according to a statement issued by ISB this week. ETH Zurich and ISB plan to collaborate via Aebersold's connections to both places, the statement indicated.
Gavin MacBeath and Jay Groves were among this year’s top 100 young innovators being honored by MIT’s Technology Review Magazine. The innovators — who were selected by the magazine’s editors and a panel of judges and must as a rule all be under age 35 — will be honored Sept. 24 to 25 at the Emerging Technologies Conference at MIT. Detailed bios are also being published in the October issue of the magazine, which became available online this week.
Groves was cited for his work with Synamem, formerly Proteomic Systems which has developed a membrane chip technology-an array of cellular membranes for drug discovery.
MacBeath, who is an assistant professor at Harvard University’s deparement of chemistry and chemical biology, is being recognized for his work developing technology for Merrimack Pharmaceuticals. Merrimack, founded in 2000 and based in Cambridge, Mass., does drug discovery work based on an approach it calls “network biology” — the study of networks of proteins and of the interactions mediating cellular pathways.
Leanna Read has been appointed non-executive director of Sydney, Australia-based Novagen. Read is a professor at Flinders University and is a board member of the CRC for Diagnostics and the Australian Proteome Analysis Facility, and is a member of the South Australian Premier’s Science and Research Council. She is also currently the CEO and managing director of TGR BioSciences.
Terrance Coyne has been appointed the new chief medical officer and vice president of clinical development at Encysive Pharmaceuticals. Coyne will now oversee the development of lead drug candidates at Encysive. He most recently served as the senior vice president and chief medical and regulatory of- ficer at St. Louis-based Metaphore Pharmaceuticals.